Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents

Surgery

Volumn 126, Issue 2, 1999, Pages 413-421

  Roh, Haeri ^a   Hirose, Christopher B ^a   Boswell, Craig B ^a   Pippin, James A ^a   Drebin, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PHOSPHOROTHIOIC ACID DERIVATIVE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032838085     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70186-8     Document Type: Article

References (25)

1. 1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochimica et Biophysica Acta 1994;1198:165-84.
2. 2. Slamon DJ, Godolphin W, Jones, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
3. 3. Alaoui-Jamali MA, Paterson J, Al Moustafa AE, et al. The role of erbB2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997;75:315-25.
4. 4. Yu D, Liu B, Tan M, et al. Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65.
5. 5. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
6. 6. Drebin JA, Link VC, Stem DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:695-706.
7. 7. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83:9129-33.
8. 8. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER-2 monoclonal antibody in patients with Her-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
9. 9. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
10. 10. Roh H, Pippin J, Boswell C, Drebin JA. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res 1998;77:85-90.
11. 11. Roh H, Pippin J, Drebin JA. Down-regulation of HER2/neu expression by antisense oligonucleotides induces apoptosis in human breast cancer cells that overexpress HER2/neu. Surg Forum 1998;99:418-9.
12. 12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
13. 13. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p 185 HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
14. 14. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40:S3-8.
15. 15. Webb SJ, Harrison DJ, Wyllic AH. Apoptosis: an overview of the process and its relevance in disease. Adv Pharmacol 1997;40:1-34.
16. 16. Leonetti C, D'Agnano I, Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Nat Cancer Inst 1996;88:419-29.
17. 17. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C raf kinase. Nature Med 1996;2:668-75.
18. 18. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
19. 19. Van Slooten HJ, Bonsing BA, Hiller AJ, et al. Outgrowth of BT474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. Br J Cancer 1995;72:22-30.
20. 20. Brodowicz T, Wiltschke C, Budinsky AC, et al. Soluble HER2/neu neutralizes biologic effects of anti-HER2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997;73:875-9.
21. 21. Stein CA, Does antisense exist? Nature Med 1995;1:1119-21.
22. 22. Crooke ST. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv Pharmacol 1997;40:1-49.
23. 23. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of Paclitaxel and Adriamycin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
24. 24. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy in humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;2235-49.
25. cdc2 kinase. Mol Cell 1998;2:581-91.